Company Name: Click Therapeutics
Founded: 2012, NYC
Annual Revenue: $5 million to $41.7 million
Total Funding: $142 million
Customer Base: undisclosed
Click Therapeutics is a cutting-edge digital health company specializing in prescription digital therapeutics (DTx). These are software-based interventions designed to treat various medical conditions by modifying patient behavior and improving outcomes. The company emphasizes the development of evidence-based digital treatments that work alongside or even replace traditional pharmacological therapies.
Key Highlights of Click Therapeutics
Founding Vision: To pioneer a new class of medicine by combining advanced technology with clinical evidence to deliver measurable health improvements.
Click’s products address a variety of conditions, including chronic diseases and mental health. Examples include:
• CT-152: A digital therapeutic for treating major depressive disorder (MDD), currently under development in partnership with Otsuka Pharmaceuticals.
• Smoking Cessation: The company developed a program to help users quit smoking by delivering cognitive behavioral therapy (CBT) and other interventions through a mobile app.
• Pain Management: Digital tools targeting chronic pain by using neurobehavioral interventions.
Click has collaborated with major pharmaceutical companies, which highlights the credibility of its solutions:
• Otsuka Pharmaceuticals: A $300 million partnership to co-develop and commercialize a digital therapeutic for MDD.
• Boehringer Ingelheim: Focused on developing digital therapeutics for schizophrenia.
TECHNOLOGY & METHODOLOGY
Click’s therapeutics are software-as-a-medical-device (SaMD) solutions. The platform utilizes behavioral psychology, machine learning, and gamification to engage patients and promote adherence. Interventions are tailored based on real-time data collected from users to ensure personalized treatment.
REGULATORY PATH
Click Therapeutics aims to achieve FDA clearance for its products, ensuring they meet rigorous standards of efficacy and safety.
Products like CT-152 are in clinical trials to gather robust data demonstrating their effectiveness.
BUSINESS MODEL
The company employs a B2B2C approach, partnering with healthcare providers, insurers, and employers. Products are often covered by insurers, prescribed by clinicians, and supported by employers for their employees.
Click is committed to generating strong clinical evidence through randomized controlled trials (RCTs), similar to traditional drug development. For instance, its ongoing trials with Otsuka aim to demonstrate the effectiveness of CT-152 for MDD.
COMPETITIVE EDGE
Focus on Cognitive Behavioral Therapy (CBT): Unlike some competitors, Click emphasizes CBT-based interventions to address the root causes of behavioral health issues.
Robust Partnerships: Its collaborations with pharmaceutical giants strengthen its market positioning and financial stability.
Patient-Centric Design: The products prioritize user engagement, which is key to adherence and treatment success.
INDUSTRY POSITION
Click is a leader in the emerging digital therapeutics market, valued at over $8 billion in 2022 and projected to grow significantly. Its focus on mental health and chronic disease aligns with global healthcare priorities.
Comments